Skip to Content


Active Substance: olanzapine
Common Name: olanzapine
ATC Code: N05AH03
Marketing Authorisation Holder: Eli Lilly & Co. Ltd.
Active Substance: olanzapine
Status: Withdrawn
Authorisation Date: 1996-10-07
Therapeutic Area: Bipolar Disorder Schizophrenia
Pharmacotherapeutic Group: Psycholeptics

Therapeutic Indication

Olanzapine is indicated for the treatment of schizophrenia.
Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.
Olanzapine is indicated for the treatment of moderate to severe manic episode. Olanzapine has not been demonstrated to prevent recurrence of manic or depressive episodes (see Section 5.1).

The marketing authorisation for Olansek has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.